Search

Your search keyword '"Connors, Jean Marie"' showing total 35 results
Start Over Author "Connors, Jean Marie"
35 results on '"Connors, Jean Marie"'

3. Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide

Author

Mo, Clifton C., Richardson, Edward, Calabretta, Eleonora, Corrado, Francesco, Kocoglu, Mehmet H., Baron, Rebecca M., Connors, Jean Marie, Iacobelli, Massimo, Wei, Lee-Jen, Rapoport, Aaron P., Díaz-Ricart, Maribel, Moraleda, José M., Carlo-Stella, Carmelo, and Richardson, Paul G.

Published
2024
Full Text
View/download PDF

5. How to manage coagulopathies in critically ill patients

Author

Helms, Julie, Iba, Toshiaki, Connors, Jean Marie, Gando, Satoshi, Levi, Marcel, Meziani, Ferhat, and Levy, Jerrold H.

Subjects
Medical research, Medicine, Experimental, Medical colleges, Company business management, Health care industry
Abstract

Coagulopathy is a severe and frequent complication in critically ill patients, for which the pathogenesis and presentation may be variable depending on the underlying disease. Based on the dominant clinical phenotype, the current review differentiates between hemorrhagic coagulopathies, characterized by a hypocoagulable and hyperfibrinolysis state, and thrombotic coagulopathies with a systemic prothrombotic and antifibrinolytic phenotype. We discuss the differences in pathogenesis and treatment of the common coagulopathies., Author(s): Julie Helms [sup.1] [sup.2], Toshiaki Iba [sup.3], Jean Marie Connors [sup.4], Satoshi Gando [sup.5] [sup.6], Marcel Levi [sup.7] [sup.8], Ferhat Meziani [sup.1] [sup.2], Jerrold H. Levy [sup.9] Author Affiliations: [...]

Published
2023
Full Text
View/download PDF

6. ISTH guidelines for antithrombotic treatment in COVID‐19

Author

Schulman, Sam, Sholzberg, Michelle, Spyropoulos, Alex C., Zarychanski, Ryan, Resnick, Helaine E., Bradbury, Charlotte A., Connors, Jean Marie, Falanga, Anna, Iba, Toshiaki, Kaatz, Scott, Levy, Jerrold H., Middeldorp, Saskia, Minichiello, Tracy, Ramacciotti, Eduardo, Samama, Charles Marc, Thachil, Jecko, Broxmeyer, Lisa, and International Society on Thrombosis and Haemostasis

Published
2022
Full Text
View/download PDF

11. Effects of a fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device on von Willebrand factor: A prospective multicenter clinical trial

Author

Bansal, Aditya, Uriel, Nir, Colombo, Paolo C., Narisetty, Keerthy, Long, James W., Bhimaraj, Arvind, Cleveland, Joseph C., Jr, Goldstein, Daniel J., Stulak, John M., Najjar, Samer S., Lanfear, David E., Adler, Eric D., Dembitsky, Walter P., Somo, Sami I., Crandall, Daniel L., Chen, Dong, Connors, Jean Marie, and Mehra, Mandeep R.

Published
2019
Full Text
View/download PDF

17. Awareness of venous thromboembolism among patients with cancer: Preliminary findings from a global initiative for World Thrombosis Day

Author

Potere, Nicola, primary, Barco, Stefano, additional, Mahé, Isabelle, additional, Cesarman‐Maus, Gabriela, additional, Angchaisuksiri, Pantep, additional, Leader, Avi, additional, Okoye, Helen C., additional, Olayemi, Edeghonghon, additional, Ay, Cihan, additional, Carrier, Marc, additional, Connors, Jean Marie, additional, Farmakis, Ioannis T., additional, Fumagalli, Riccardo M., additional, Jing, Zhi‐Cheng, additional, Lee, Lai Heng, additional, McLintock, Claire, additional, Ní Ainle, Fionnuala, additional, Giannakoulas, George, additional, Goto, Shinya, additional, Guillermo Esposito, Maria Cecilia, additional, Jara‐Palomares, Luis, additional, Szlaszynska, Marta, additional, Tan, Chee Wee, additional, Van Es, Nick, additional, Wang, Tzu‐Fei, additional, Hunt, Beverley J., additional, and Di Nisio, Marcello, additional

Published
2022
Full Text
View/download PDF

25. ISTHguidelines for antithrombotic treatment in COVID‐19

Author

Schulman, Sam, Sholzberg, Michelle, Spyropoulos, Alex C., Zarychanski, Ryan, Resnick, Helaine E., Bradbury, Charlotte A., Broxmeyer, Lisa, Connors, Jean Marie, Falanga, Anna, Iba, Toshiaki, Kaatz, Scott, Levy, Jerrold H., Middeldorp, Saskia, Minichiello, Tracy, Ramacciotti, Eduardo, Samama, Charles Marc, and Thachil, Jecko

Abstract

Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins. Optimal dosing and timing of these treatments and benefits of other antithrombotic agents remain unclear. In October 2021, ISTH assembled an international panel of content experts, patient representatives, and a methodologist to develop recommendations on anticoagulants and antiplatelet agents for patients with COVID‐19 in different clinical settings. We used the American College of Cardiology Foundation/American Heart Association methodology to assess level of evidence (LOE) and class of recommendation (COR). Only recommendations with LOE A or B were included. Panelists agreed on 12 recommendations: three for non‐hospitalized, five for non–critically ill hospitalized, three for critically ill hospitalized, and one for post‐discharge patients. Two recommendations were based on high‐quality evidence, the remainder on moderate‐quality evidence. Among non–critically ill patients hospitalized for COVID‐19, the panel gave a strong recommendation (a) for use of prophylactic dose of low molecular weight heparin or unfractionated heparin (LMWH/UFH) (COR 1); (b) for select patients in this group, use of therapeutic dose LMWH/UFH in preference to prophylactic dose (COR 1); but (c) against the addition of an antiplatelet agent (COR 3). Weak recommendations favored (a) sulodexide in non‐hospitalized patients, (b) adding an antiplatelet agent to prophylactic LMWH/UFH in select critically ill, and (c) prophylactic rivaroxaban for select patients after discharge (all COR 2b). Recommendations in this guideline are based on high‐/moderate‐quality evidence available through March 2022. Focused updates will incorporate future evidence supporting changes to these recommendations.

Published
2022
Full Text
View/download PDF

26. Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID‐19

Author

Spyropoulos, Alex C., primary, Levy, Jerrold H., additional, Ageno, Walter, additional, Connors, Jean Marie, additional, Hunt, Beverley J., additional, Iba, Toshiaki, additional, Levi, Marcel, additional, Samama, Charles Marc, additional, Thachil, Jecko, additional, Giannis, Dimitrios, additional, and Douketis, James D., additional

Published
2020
Full Text
View/download PDF

32. Cord blood leptin and insulin-like growth factor levels are independent predictors of fetal growth

Author

Papathanassoglou, Elizabeth, Christou, Helen, Connors, Jean Marie, and Παπαθανάσογλου, Ελισάβετ

Subjects
Leptin, Endocrinology, Metabolism, Hydrocortisone, Birth weight, MEDICAL AND HEALTH SCIENCES, Insulin, Fetus--Development
Abstract

The insulin-like growth factor (IGF) system is the dominant endocrine regulator of fetal growth, whereas insulin has a permissive role. Although a role for leptin in fetal growth has been suggested recently, the mechanism by which leptin may be related to fetal growth is not known; but leptin may interact with the IGF system in utero as it does in the extrauterine life. In the context of a hospital-based case control study, we collected anthropometric and demographic data and measured serum leptin, IGF-I, IGF-II, insulin, cortisol, and IGF binding protein 3 concentrations in 142 cord blood samples from full-term deliveries. Cord leptin, IGF-I, and insulin levels correlated positively with birth weight (r = 0.46, r = 0.41, and r = 0.21, respectively, P < 0.01) by univariate analysis and were significantly higher in large-for-gestational-age (LGA) infants, compared with appropriate-for-gestational-age (AGA) infants. Cord leptin concentrations correlated with insulin levels (r = 0.36, P

Published
2001

34. Dabigatran

Author

Reddy, Prabashni, primary, Atay, Julie K., additional, Selbovitz, Leslie G., additional, Connors, Jean Marie, additional, Piazza, Gregory, additional, Block, Caroline Cole, additional, Arpino, Paul A., additional, Berliner, Nancy, additional, Hutter, Adolph M., additional, Fischer, Michael A., additional, Kuter, David, additional, Weitzman, James, additional, Sherwood, Geoffery K., additional, Almozlino, Avraham, additional, and Giugliano, Robert P., additional

Published
2011
Full Text
View/download PDF

35. Dabigatran: a review of clinical and pharmacoeconomic evidence.

Author

Reddy P, Atay JK, Selbovitz LG, Connors JM, Piazza G, Block CC, Arpino PA, Berliner N, Hutter AM Jr, Fischer MA, Kuter D, Weitzman J, Sherwood GK, Almozlino A, and Giugliano RP

Subjects
Antithrombin Proteins, Benzimidazoles economics, Cost-Benefit Analysis, Dabigatran, Economics, Pharmaceutical, Humans, Pyridines economics, Quality of Life, Venous Thromboembolism blood, Benzimidazoles pharmacology, Pyridines pharmacology, Venous Thromboembolism prevention & control
Abstract

Dabigatran etexilate is the first commercially available oral direct thrombin inhibitor. A single trial has studied patients at risk for stroke associated with nonvalvular atrial fibrillation; in this trial, dabigatran 150 mg twice a day met the criteria for superiority over warfarin in preventing stroke and systemic embolism while reducing the rate of hemorrhagic stroke with a similar risk of major bleeding. For the treatment of venous thromboembolism, dabigatran 150 mg twice a day had comparable efficacy and safety versus warfarin. In contrast, dabigatran was less effective than enoxaparin 30 mg twice a day in venous thromboembolism prevention in orthopedic surgery. Advantages of dabigatran over warfarin include its lack of need for routine laboratory monitoring, a fixed-dose regimen, and potentially fewer clinically important drug interactions. Concerns include higher incidences of dyspepsia and gastrointestinal bleeding, twice-daily dosing, and lack of effective antidote. Additional drawbacks include higher drug cost versus warfarin, accumulation in case of renal impairment, higher discontinuation rates due to adverse events, and limited long-term safety and trial data. From a payer perspective, overall costs will be higher with dabigatran compared with warfarin, but dabigatran does meet the threshold to be considered a cost-effective therapy. In addition, the lack of need for regular laboratory monitoring is a quality of life advantage for patients on dabigatran. These observations suggest that dabigatran is a valuable addition to the therapeutic armamentarium for stroke prevention in selected patients with atrial fibrillation although caution should be exercised given the limited data on this agent and higher cost.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results